Business Context and Reporting Period
This Form 8-K is a Current Report filed by Qualigen Therapeutics, Inc. (not Aixcrypto Holdings, Inc.) on September 26, 2025. The filing reports a corporate governance event: the appointment of a new independent director to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the addition of Kevin Chen as an independent member of the Board of Directors, effective immediately on September 26, 2025. As of the filing date, Mr. Chen has not been appointed to any specific board committees.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future performance. It includes a detailed biography of the new appointee, Kevin Chen, highlighting his background as Chief Economist and CIO of Horizon Financial, his previous roles at Morgan Stanley and Credit Agricole/Amundi, and his extensive board experience with other public companies.
Key Facts for Investor Verification
- Verify the correct registrant name is Qualigen Therapeutics, Inc. (Ticker: QLGN), not Aixcrypto Holdings, Inc.
- Confirm the effective date of Kevin Chen's board appointment is September 26, 2025.
- Note that the new director has not yet been assigned to any board committees.
- Review Mr. Chen's extensive background in finance and prior board roles for potential conflicts of interest or strategic alignment.